Episurf Medical and European Clinics to report 2 year clinical results of a customised metal mini-prosthesis in the knee at a major European Clinical congress

The scientific results of Episurf’s knee implant (Episealer) are to be presented at the prestigious AGA congress (German Society for Arthroscopy and Joint Surgery) in Basel on Friday 16th September. The scientific abstract “The chondral lesion in GAP patients: up to 2-year clinical results using a customised metal mini-prosthesis in the knee” will be presented by Dr. Leif Ryd. The multi-centre data is compiled from European clinics.

This information was published, 2016-09-16 13:15 CEST (GLOBE NEWSWIRE) —

The presentation will demonstrate that Episealer patients with focal chondral lesions of the knee with failed previous biological surgeries, are reporting a significant reduction in pain whilst their quality of life improves. The presented data comprises results from 11 patients that received the Episealer device in four different European countries and have been followed for 24 months.

“The study found that patients who had previously been unsuccessfully treated with biological solutions, demonstrated significant improvements in their quality of life after receiving the Episealer implant. These patients have traditionally fallen into what is becoming known as a “treatment gap”; they are too young for joint replacement surgery but have exhausted all options to repair their cartilage. The results of this study show that the Episealer can help these patients get back to a more normal lifestyle, such as returning to work. These are significant results that demonstrate the safety of the implant” comments Dr. Ryd.

Rosemary Cunningham Thomas, CEO of Episurf Medical says that the results being delivered in this presentation are consolidating the experiences that are reported daily by Episealer patients and their surgeons.

“In line with a key 2016 strategic initiative of building robust clinical evidence, we now have accumulated clinical evidence that demonstrates very good implant safety and patient well-being. 2 years’ follow-up is generally considered an accepted threshold for clinical success. We can therefore expect increased acceptance from the orthopaedic profession”, says Rosemary Cunningham Thomas, CEO, Episurf Medical.


For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical

Tel: +46 (0) 70-7655892

Tel: +44 (0) 7803-753603

Email: rosemary@episurf.com


About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.15 CET on 16 September 2016.